S3-Leitlinie „Exokrines Pankreaskarzinom” 2007

 

 Permissions and Reprints

Im Auftrag der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Krebsgesellschaft (DKG).

In Zusammenarbeit mit der/dem

Arbeitsgemeinschaft Radiologische Onkologie der Deutschen Krebsgesellschaft (ARO) Arbeitskreis der Pankreatektomierten e. V. Deutschen Gesellschaft für Chirurgie (DGCH) Deutschen Gesellschaft für Hämatologie und Onkologie (DGHO) Deutschen Gesellschaft für Palliativmedizin Deutschen Gesellschaft für Pathologie (DGP) Deutschen Gesellschaft für Radioonkologie (DEGRO) Deutschen Gesellschaft für Viszeralchirurgie (CAO-V)/Chirurgischen Arbeitsgemeinschaft Onkologie (CAO-V) Deutschen Röntgengesellschaft (DRG) Deutschen Vereinten Gesellschaft für Klinische Chemie und Laboratoriumsmedizin (DGKL)

Leitung: G. Adler, T. Seufferlein, I. Kopp

Literatur

• 1 Glade M J. Food, nutrition, and the prevention of cancer: a global perspective. American Institute for Cancer Research/World Cancer Research Fund, American Institute for Cancer Research, 1997.  Nutrition. 1999;  15 523-526
  Google Scholar
• 2 Fernandez E, La Vecchia C, Decarli A. Attributable risks for pancreatic cancer in northern Italy.  Cancer Epidemiol Biomarkers Prev. 1996;  5 23-27
  Google Scholar
• 3 Ji B T, Chow W H, Gridley G. et al . Dietary factors and the risk of pancreatic cancer: a case-control study in Shanghai China.  Cancer Epidemiol Biomarkers Prev. 1995;  4 885-893
  Google Scholar
• 4 Soler M, Chatenoud L, La Vecchia C. et al . Diet, alcohol, coffee and pancreatic cancer: final results from an Italian study.  Eur J Cancer Prev. 1998;  7 455-460
  Google Scholar
• 5 Nkondjock A, Krewski D, Johnson K C. et al . Dietary patterns and risk of pancreatic cancer.  Int J Cancer. 2005;  114 817-823
  Google Scholar
• 6 Nothlings U, Wilkens L R, Murphy S P. et al . Meat and fat intake as risk factors for pancreatic cancer: the multiethnic cohort study.  J Natl Cancer Inst. 2005;  97 1458-1465
  Google Scholar
• 7 Michaud D S, Giovannucci E, Willett W C. et al . Dietary meat, dairy products, fat, and cholesterol and pancreatic cancer risk in a prospective study.  Am J Epidemiol. 2003;  157 1115-1125
  Google Scholar
• 8 Michaud D S, Skinner H G, Wu K. et al . Dietary patterns and pancreatic cancer risk in men and women.  J Natl Cancer Inst. 2005;  97 518-524
  Google Scholar
• 9 Hine R J, Srivastava S, Milner J A. et al . Nutritional links to plausible mechanisms underlying pancreatic cancer: a conference report.  Pancreas. 2003;  27 356-366
  Google Scholar
• 10 Bueno de Mesquita H B, Maisonneuve P, Runia S. et al . Intake of foods and nutrients and cancer of the exocrine pancreas: a population-based case-control study in The Netherlands.  Int J Cancer. 1991;  48 540-549
  Google Scholar
• 11 Lyon J L, Slattery M L, Mahoney A W. et al . Dietary intake as a risk factor for cancer of the exocrine pancreas.  Cancer Epidemiol Biomarkers Prev. 1993;  2 513-518
  Google Scholar
• 12 Fraser G E. Associations between diet and cancer, ischemic heart disease, and all-cause mortality in non-Hispanic white California Seventh-day Adventists.  Am J Clin Nutr. 1999;  70 532S-538S
  Google Scholar
• 13 Mills P K, Beeson W L, Abbey D E. et al . Dietary habits and past medical history as related to fatal pancreas cancer risk among Adventists.  Cancer. 1988;  61 2578-2585
  Google Scholar
• 14 Chan J M, Wang F, Holly E A. Vegetable and fruit intake and pancreatic cancer in a population-based case-control study in the San Francisco bay area.  Cancer Epidemiol Biomarkers Prev. 2005;  14 2093-2097
  Google Scholar
• 15 Negri E, La Vecchia C, Franceschi S. et al . Vegetable and fruit consumption and cancer risk.  Int J Cancer. 1991;  48 350-354
  Google Scholar
• 16 Larsson S C, Hakansson N, Naslund I. et al . Fruit and vegetable consumption in relation to pancreatic cancer risk: a prospective study.  Cancer Epidemiol Biomarkers Prev. 2006;  15 301-305
  Google Scholar
• 17 Vainio H, Weiderpass E. Fruit and vegetables in cancer prevention.  Nutr Cancer. 2006;  54 111-142
  Google Scholar
• 18 Lin Y, Tamakoshi A, Hayakawa T. et al . Nutritional factors and risk of pancreatic cancer: a population-based case-control study based on direct interview in Japan.  J Gastroenterol. 2005;  40 297-301
  Google Scholar
• 19 Stolzenberg-Solomon R Z, Pietinen P, Taylor P R. et al . Prospective study of diet and pancreatic cancer in male smokers.  Am J Epidemiol. 2002;  155 783-792
  Google Scholar
• 20 Zhang J, Zhao Z, Berkel H J. Animal fat consumption and pancreatic cancer incidence: evidence of interaction with cigarette smoking.  Ann Epidemiol. 2005;  15 500-508
  Google Scholar
• 21 Anderson K E, Sinha R, Kulldorff M. et al . Meat intake and cooking techniques: associations with pancreatic cancer.  Mutat Res. 2002;  506 - 507 225-231
  Google Scholar
• 22 Anderson K E, Kadlubar F F, Kulldorff M. et al . Dietary intake of heterocyclic amines and benzo(a)pyrene: associations with pancreatic cancer.  Cancer Epidemiol Biomarkers Prev. 2005;  14 2261-2265
  Google Scholar
• 23 Ghadirian P, Baillargeon J, Simard A. et al . Food habits and pancreatic cancer: a case-control study of the Francophone community in Montreal, Canada.  Cancer Epidemiol Biomarkers Prev. 1995;  4 895-899
  Google Scholar
• 24 Fernandez E, Chatenoud L, La Vecchia C. et al . Fish consumption and cancer risk.  Am J Clin Nutr. 1999;  70 85-90
  Google Scholar
• 25 Michaud D S, Liu S, Giovannucci E. et al . Dietary sugar, glycemic load, and pancreatic cancer risk in a prospective study.  J Natl Cancer Inst. 2002;  94 1293-1300
  Google Scholar
• 26 Silvera S A, Rohan T E, Jain M. et al . Glycemic index, glycemic load, and pancreatic cancer risk (Canada).  Cancer Causes Control. 2005;  16 431-436
  Google Scholar
• 27 Schernhammer E S, Hu F B, Giovannucci E. et al . Sugar-sweetened soft drink consumption and risk of pancreatic cancer in two prospective cohorts.  Cancer Epidemiol Biomarkers Prev. 2005;  14 2098-2105
  Google Scholar
• 28 Lin Y, Tamakoshi A, Kawamura T. et al . Risk of pancreatic cancer in relation to alcohol drinking, coffee consumption and medical history: findings from the Japan collaborative cohort study for evaluation of cancer risk.  Int J Cancer. 2002;  99 742-746
  Google Scholar
• 29 Michaud D S, Giovannucci E, Willett W C. et al . Coffee and alcohol consumption and the risk of pancreatic cancer in two prospective United States cohorts.  Cancer Epidemiol Biomarkers Prev. 2001;  10 429-437
  Google Scholar
• 30 Silverman D T. Risk factors for pancreatic cancer: a case-control study based on direct interviews.  Teratog Carcinog Mutagen. 2001;  21 7-25
  Google Scholar
• 31 Brown L M. Epidemiology of alcohol-associated cancers.  Alcohol. 2005;  35 161-168
  Google Scholar
• 32 Ye W, Lagergren J, Weiderpass E. et al . Alcohol abuse and the risk of pancreatic cancer.  Gut. 2002;  51 236-239
  Google Scholar
• 33 Talamini G, Bassi C, Falconi M. et al . Alcohol and smoking as risk factors in chronic pancreatitis and pancreatic cancer.  Dig Dis Sci. 1999;  44 1303-1311
  Google Scholar
• 34 MacMahon B, Yen S, Trichopoulos D. et al . Coffee and cancer of the pancreas.  N Engl J Med. 1981;  304 630-633
  Google Scholar
• 35 Gullo L, Pezzilli R, Morselli-Labate A M. Coffee and cancer of the pancreas: an Italian multicenter study. The Italian Pancreatic Cancer Study Group.  Pancreas. 1995;  11 223-229
  Google Scholar
• 36 Lyon J L, Mahoney A W, French T K. et al . Coffee consumption and the risk of cancer of the exocrine pancreas: a case-control study in a low-risk population.  Epidemiology. 1992;  3 164-170
  Google Scholar
• 37 Harnack L J, Anderson K E, Zheng W. et al . Smoking, alcohol, coffee, and tea intake and incidence of cancer of the exocrine pancreas: the Iowa Women’s Health Study.  Cancer Epidemiol Biomarkers Prev. 1997;  6 1081-1086
  Google Scholar
• 38 Qiu D, Kurosawa M, Lin Y. et al . Overview of the epidemiology of pancreatic cancer focusing on the JACC Study.  J Epidemiol. 2005;  15 (Suppl 2) S157-167
  Google Scholar
• 39 Tavani A, La Vecchia C. Coffee and cancer: a review of epidemiological studies, 1990 - 1999.  Eur J Cancer Prev. 2000;  9 241-256
  Google Scholar
• 40 La Vecchia C, Negri E, Franceschi S. et al . Tea consumption and cancer risk.  Nutr Cancer. 1992;  17 27-31
  Google Scholar
• 41 Nagano J, Kono S, Preston D L. et al . A prospective study of green tea consumption and cancer incidence, Hiroshima and Nagasaki (Japan).  Cancer Causes Control. 2001;  12 501-508
  Google Scholar
• 42 Hemminki K, Dong C, Vaittinen P. Cancer risks to spouses and offspring in the Family-Cancer Database.  Genet Epidemiol. 2001;  20 247-257
  Google Scholar
• 43 Hemminki K, Jiang Y. Cancer risks among long-standing spouses.  Br J Cancer. 2002;  86 1737-1740
  Google Scholar
• 44 Nilsen T I, Vatten L J. A prospective study of lifestyle factors and the risk of pancreatic cancer in Nord-Trondelag, Norway.  Cancer Causes Control. 2000;  11 645-652
  Google Scholar
• 45 Berrington de Gonzalez A, Sweetland S, Spencer E. A meta-analysis of obesity and the risk of pancreatic cancer.  Br J Cancer. 2003;  89 519-523
  Google Scholar
• 46 Michaud D S, Giovannucci E, Willett W C. et al . Physical activity, obesity, height, and the risk of pancreatic cancer.  Jama. 2001;  286 921-929
  Google Scholar
• 47 Patel A V, Rodriguez C, Bernstein L. et al . Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. Cohort.  Cancer Epidemiol Biomarkers Prev. 2005;  14 459-466
  Google Scholar
• 48 Rapp K, Schroeder J, Klenk J. et al . Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria.  Br J Cancer. 2005;  93 1062-1067
  Google Scholar
• 49 Larsson S C, Permert J, Hakansson N. et al . Overall obesity, abdominal adiposity, diabetes and cigarette smoking in relation to the risk of pancreatic cancer in two Swedish population-based cohorts.  Br J Cancer. 2005;  93 1310-1315
  Google Scholar
• 50 Berrington de Gonzalez A, Spencer E A, Bueno-de-Mesquita H B. et al . Anthropometry, physical activity, and the risk of pancreatic cancer in the European prospective investigation into cancer and nutrition.  Cancer Epidemiol Biomarkers Prev. 2006;  15 879-885
  Google Scholar
• 51 Silverman D T, Swanson C A, Gridley G. et al . Dietary and nutritional factors and pancreatic cancer: a case-control study based on direct interviews.  J Natl Cancer Inst. 1998;  90 1710-1719
  Google Scholar
• 52 Stolzenberg-Solomon R Z, Pietinen P, Taylor P R. et al . A prospective study of medical conditions, anthropometry, physical activity, and pancreatic cancer in male smokers (Finland).  Cancer Causes Control. 2002;  13 417-426
  Google Scholar
• 53 Hanley A J, Johnson K C, Villeneuve P J. et al . Physical activity, anthropometric factors and risk of pancreatic cancer: results from the Canadian enhanced cancer surveillance system.  Int J Cancer. 2001;  94 140-147
  Google Scholar
• 54 Coughlin S S, Calle E E, Patel A V. et al . Predictors of pancreatic cancer mortality among a large cohort of United States adults.  Cancer Causes Control. 2000;  11 915-923
  Google Scholar
• 55 Lin Y, Tamakoshi A, Kawamura T. et al . A prospective cohort study of cigarette smoking and pancreatic cancer in Japan.  Cancer Causes Control. 2002;  13 249-254
  Google Scholar
• 56 Yun Y H, Jung K W, Bae J M. et al . Cigarette smoking and cancer incidence risk in adult men: National Health Insurance Corporation Study.  Cancer Detect Prev. 2005;  29 15-24
  Google Scholar
• 57 Chiu B C, Lynch C F, Cerhan J R. et al . Cigarette smoking and risk of bladder, pancreas, kidney, and colorectal cancers in Iowa.  Ann Epidemiol. 2001;  11 28-37
  Google Scholar
• 58 Bonelli L, Aste H, Bovo P. et al . Exocrine pancreatic cancer, cigarette smoking, and diabetes mellitus: a case-control study in northern Italy.  Pancreas. 2003;  27 143-149
  Google Scholar
• 59 Duell E J, Holly E A, Bracci P M. et al . A population-based, case-control study of polymorphisms in carcinogen-metabolizing genes, smoking, and pancreatic adenocarcinoma risk.  J Natl Cancer Inst. 2002;  94 297-306
  Google Scholar
• 60 Miyasaka K, Kawanami T, Shimokata H. et al . Inactive aldehyde dehydrogenase-2 increased the risk of pancreatic cancer among smokers in a Japanese male population.  Pancreas. 2005;  30 95-98
  Google Scholar
• 61 Wang L, Miao X, Tan W. et al . Genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase and risk of pancreatic cancer.  Clin Gastroenterol Hepatol. 2005;  3 743-751
  Google Scholar
• 62 Villeneuve P J, Johnson K C, Mao Y. et al . Environmental tobacco smoke and the risk of pancreatic cancer: findings from a Canadian population-based case-control study.  Can J Public Health. 2004;  95 32-37
  Google Scholar
• 63 Alguacil J, Pollan M, Gustavsson P. Occupations with increased risk of pancreatic cancer in the Swedish population.  Occup Environ Med. 2003;  60 570-576
  Google Scholar
• 64 Alguacil J, Porta M, Benavides F G. et al . Occupation and pancreatic cancer in Spain: a case-control study based on job titles. PANKRAS II Study Group.  Int J Epidemiol. 2000;  29 1004-1013
  Google Scholar
• 65 Laakkonen A, Kauppinen T, Pukkala E. Cancer risk among Finnish food industry workers.  Int J Cancer. 2006;  118 2567-2571
  Google Scholar
• 66 Fryzek J P, Garabrant D H, Harlow S D. et al . A case-control study of self-reported exposures to pesticides and pancreas cancer in southeastern Michigan.  Int J Cancer. 1997;  72 62-67
  Google Scholar
• 67 Ji B T, Silverman D T, Stewart P A. et al . Occupational exposure to pesticides and pancreatic cancer.  Am J Ind Med. 2001;  39 92-99
  Google Scholar
• 68 Ojajarvi I A, Partanen T J, Ahlbom A. et al . Occupational exposures and pancreatic cancer: a meta-analysis.  Occup Environ Med. 2000;  57 316-324
  Google Scholar
• 69 Ojajarvi A, Partanen T, Ahlbom A. et al . Risk of pancreatic cancer in workers exposed to chlorinated hydrocarbon solvents and related compounds: a meta-analysis.  Am J Epidemiol. 2001;  153 841-850
  Google Scholar
• 70 Weiderpass E, Vainio H, Kauppinen T. et al . Occupational exposures and gastrointestinal cancers among Finnish women.  J Occup Environ Med. 2003;  45 305-315
  Google Scholar
• 71 Yassi A, Tate R B, Routledge M. Cancer incidence and mortality in workers employed at a transformer manufacturing plant: update to a cohort study.  Am J Ind Med. 2003;  44 58-62
  Google Scholar
• 72 Ji J, Hemminki K. Socioeconomic and occupational risk factors for pancreatic cancer: a cohort study in Sweden.  J Occup Environ Med. 2006;  48 283-288
  Google Scholar
• 73 Bjelakovic G, Nikolova D, Simonetti R G. et al . Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis.  Lancet. 2004;  364 1219-1228
  Google Scholar
• 74 Bjelakovic G, Nikolova D, Simonetti R G. et al . Antioxidant supplements for preventing gastrointestinal cancers.  Cochrane Database Syst Rev CD004183. 2004; 
  Google Scholar
• 75 Harris R E, Beebe-Donk J, Doss H. et al . Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review).  Oncol Rep. 2005;  13 559-583
  Google Scholar
• 76 Jacobs E J, Connell C J, Rodriguez C. et al . Aspirin use and pancreatic cancer mortality in a large United States cohort.  J Natl Cancer Inst. 2004;  96 524-528
  Google Scholar
• 77 Coogan P F, Rosenberg L, Palmer J R. et al . Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel.  Cancer Epidemiol Biomarkers Prev. 2000;  9 119-123
  Google Scholar
• 78 Homma T, Tsuchiya R. The study of the mass screening of persons without symptoms and of the screening of outpatients with gastrointestinal complaints or icterus for pancreatic cancer in Japan, using CA 19-9 and elastase-1 or ultrasonography.  Int J Pancreatol. 1991;  9 119-124
  Google Scholar
• 79 Kim J E, Lee K T, Lee J K. et al . Clinical usefulness of carbohydrate antigen 19 - 9 as a screening test for pancreatic cancer in an asymptomatic population.  J Gastroenterol Hepatol. 2004;  19 182-186
  Google Scholar
• 80 McWilliams R R, Rabe K G, Olswold C. et al . Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma.  Cancer. 2005;  104 388-394
  Google Scholar
• 81 Klein A P, Brune K A, Petersen G M. et al . Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds.  Cancer Res. 2004;  64 2634-2638
  Google Scholar
• 82 Bartsch D K, Sina-Frey M, Lang S. et al . CDKN2A germline mutations in familial pancreatic cancer.  Ann Surg. 2002;  236 730-737
  Google Scholar
• 83 McFaul C D, Greenhalf W, Earl J. et al . Anticipation in familial pancreatic cancer.  Gut. 2006;  55 252-258
  Google Scholar
• 84 Tersmette A C, Petersen G M, Offerhaus G J. et al . Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer.  Clin Cancer Res. 2001;  7 738-744
  Google Scholar
• 85 Brentnall T A. Management strategies for patients with hereditary pancreatic cancer.  Curr Treat Options Oncol. 2005;  6 437-445
  Google Scholar
• 86 Canto M I, Goggins M, Yeo C J. et al . Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach.  Clin Gastroenterol Hepatol. 2004;  2 606-621
  Google Scholar
• 87 Canto M I, Goggins M, Hruban R H. et al . Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study.  Clin Gastroenterol Hepatol. 2006;  4 766-781; quiz 665
  Google Scholar
• 88 Giardiello F M, Brensinger J D, Tersmette A C. et al . Very high risk of cancer in familial Peutz-Jeghers syndrome.  Gastroenterology. 2000;  119 1447-1453
  Google Scholar
• 89 Lim W, Olschwang S, Keller J J. et al . Relative frequency and morphology of cancers in STK11 mutation carriers.  Gastroenterology. 2004;  126 1788-1794
  Google Scholar
• 90 Lynch H T, Brand R E, Hogg D. et al . Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome.  Cancer. 2002;  94 84-96
  Google Scholar
• 91 Rulyak S J, Brentnall T A, Lynch H T. et al . Characterization of the neoplastic phenotype in the familial atypical multiple-mole melanoma-pancreatic carcinoma syndrome.  Cancer. 2003;  98 798-804
  Google Scholar
• 92 Vasen H F, Gruis N A, Frants R R. et al . Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden).  Int J Cancer. 2000;  87 809-811
  Google Scholar
• 93 Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian.  MedGenMed. 2005;  7 60
  Google Scholar
• 94 Asperen C J van, Brohet R M, Meijers-Heijboer E J. et al . Cancer risks in BRCA2 families: estimates for sites other than breast and ovary.  J Med Genet. 2005;  42 711-719
  Google Scholar
• 95 Thompson D, Easton D F. Cancer Incidence in BRCA1 mutation carriers.  J Natl Cancer Inst. 2002;  94 1358-1365
  Google Scholar
• 96 Lilley M, Gilchrist D. The hereditary spectrum of pancreatic cancer: the Edmonton experience.  Can J Gastroenterol. 2004;  18 17-21
  Google Scholar
• 97 Aarnio M, Sankila R, Pukkala E. et al . Cancer risk in mutation carriers of DNA-mismatch-repair genes.  Int J Cancer. 1999;  81 214-218
  Google Scholar
• 98 Geoffroy-Perez B, Janin N, Ossian K. et al . Cancer risk in heterozygotes for ataxia-telangiectasia.  Int J Cancer. 2001;  93 288-293
  Google Scholar
• 99 Giardiello F M, Offerhaus G J, Lee D H. et al . Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis.  Gut. 1993;  34 1394-1396
  Google Scholar
• 100 Couch F J, Johnson M R, Rabe K. et al . Germ line Fanconi anemia complementation group C mutations and pancreatic cancer.  Cancer Res. 2005;  65 383-386
  Google Scholar
• 101 Howes N, Lerch M M, Greenhalf W. et al . Clinical and genetic characteristics of hereditary pancreatitis in Europe.  Clin Gastroenterol Hepatol. 2004;  2 252-261
  Google Scholar
• 102 Lowenfels A B, Maisonneuve P, DiMagno E P. et al . Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group.  J Natl Cancer Inst. 1997;  89 442-446
  Google Scholar
• 103 Kimmey M B, Bronner M P, Byrd D R. et al . Screening and surveillance for hereditary pancreatic cancer.  Gastrointest Endosc. 2002;  56 S82-86
  Google Scholar
• 104 Bansal P, Sonnenberg A. Pancreatitis is a risk factor for pancreatic cancer.  Gastroenterology. 1995;  109 247-251
  Google Scholar
• 105 Karlson B M, Ekbom A, Josefsson S. et al . The risk of pancreatic cancer following pancreatitis: an association due to confounding?.  Gastroenterology. 1997;  113 587-592
  Google Scholar
• 106 Lowenfels A B, Maisonneuve P, Cavallini G. et al . Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group.  N Engl J Med. 1993;  328 1433-1437
  Google Scholar
• 107 Malka D, Hammel P, Maire F. et al . Risk of pancreatic adenocarcinoma in chronic pancreatitis.  Gut. 2002;  51 849-852
  Google Scholar
• 108 Talamini G, Falconi M, Bassi C. et al . Incidence of cancer in the course of chronic pancreatitis.  Am J Gastroenterol. 1999;  94 1253-1260
  Google Scholar
• 109 Chari S T, Leibson C L, Rabe K G. et al . Probability of pancreatic cancer following diabetes: a population-based study.  Gastroenterology. 2005;  129 504-511
  Google Scholar
• 110 Coughlin S S, Calle E E, Teras L R. et al . Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults.  Am J Epidemiol. 2004;  159 1160-1167
  Google Scholar
• 111 Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A. et al . Type-II diabetes and pancreatic cancer. A meta-analysis of 36 studies.  Br J Cancer. 2005;  92 2076-2083
  Google Scholar
• 112 Stolzenberg-Solomon R Z, Graubard B I, Chari S. et al . Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers.  Jama. 2005;  294 2872-2878
  Google Scholar
• 113 Wideroff L, Gridley G, Mellemkjaer L. et al . Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark.  J Natl Cancer Inst. 1997;  89 1360-1365
  Google Scholar
• 114 Calle E E, Murphy T K, Rodriguez C. et al . Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults.  Cancer Causes Control. 1998;  9 403-410
  Google Scholar
• 115 Chow W H, Gridley G, Nyren O. et al . Risk of pancreatic cancer following diabetes mellitus: a nationwide cohort study in Sweden.  J Natl Cancer Inst. 1995;  87 930-931
  Google Scholar
• 116 Silverman D T, Schiffman M, Everhart J. et al . Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer.  Br J Cancer. 1999;  80 1830-1837
  Google Scholar
• 117 Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis.  Jama. 1995;  273 1605-1609
  Google Scholar
• 118 Gullo L, Pezzilli R, Morselli-Labate A M. Diabetes and the risk of pancreatic cancer. Italian Pancreatic Cancer Study Group.  N Engl J Med. 1994;  331 81-84
  Google Scholar
• 119 Rousseau M C, Parent M E, Pollak M N. et al . Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada.  Int J Cancer. 2006;  118 2105-2109
  Google Scholar
• 120 Bjornsson E, Ismael S, Nejdet S. et al . Severe jaundice in Sweden in the new millennium: causes, investigations, treatment and prognosis.  Scand J Gastroenterol. 2003;  38 86-94
  Google Scholar
• 121 Reisman Y, Gips C H, Lavelle S M. et al . Clinical presentation of (subclinical) jaundice - the Euricterus project in The Netherlands. United Dutch Hospitals and Euricterus Project Management Group.  Hepatogastroenterology. 1996;  43 1190-1195
  Google Scholar
• 122 Watanabe I, Sasaki S, Konishi M. et al . Onset symptoms and tumor locations as prognostic factors of pancreatic cancer.  Pancreas. 2004;  28 160-165
  Google Scholar
• 123 Balthazar E J. Pancreatitis associated with pancreatic carcinoma. Preoperative diagnosis: role of CT imaging in detection and evaluation.  Pancreatology. 2005;  5 330-344
  Google Scholar
• 124 Mujica V R, Barkin J S, Go V L. Acute pancreatitis secondary to pancreatic carcinoma. Study Group Participants.  Pancreas. 2000;  21 329-332
  Google Scholar
• 125 Adamek H E, Albert J, Breer H. et al . Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study.  Lancet. 2000;  356 190-193
  Google Scholar
• 126 Hanninen E L, Ricke J, Amthauer H. et al . Magnetic resonance cholangiopancreatography: image quality, ductal morphology, and value of additional T2- and T1-weighted sequences for the assessment of suspected pancreatic cancer.  Acta Radiol. 2005;  46 117-125
  Google Scholar
• 127 Forsmark C E, Lambiase L, Vogel S B. Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA 19-9.  Pancreas. 1994;  9 731-734
  Google Scholar
• 128 Nazli O, Bozdag A D, Tansug T. et al . The diagnostic importance of CEA and CA 19 - 9 for the early diagnosis of pancreatic carcinoma.  Hepatogastroenterology. 2000;  47 1750-1752
  Google Scholar
• 129 Ritts R E Jr, Nagorney D M, Jacobsen D J. et al . Comparison of preoperative serum CA 19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease.  Pancreas. 1994;  9 707-716
  Google Scholar
• 130 Tessler D A, Catanzaro A, Velanovich V. et al . Predictors of cancer in patients with suspected pancreatic malignancy without a tissue diagnosis.  Am J Surg. 2006;  191 191-197
  Google Scholar
• 131 Agarwal B, Abu-Hamda E, Molke K L. et al . Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer.  Am J Gastroenterol. 2004;  99 844-850
  Google Scholar
• 132 Klapman J B, Chang K J, Lee J G. et al . Negative predictive value of endoscopic ultrasound in a large series of patients with a clinical suspicion of pancreatic cancer.  Am J Gastroenterol. 2005;  100 2658-2661
  Google Scholar
• 133 Varadarajulu S, Wallace M B. Applications of endoscopic ultrasonography in pancreatic cancer.  Cancer Control. 2004;  11 15-22
  Google Scholar
• 134 David O, Green L, Reddy V. et al . Pancreatic masses: a multi-institutional study of 364 fine-needle aspiration biopsies with histopathologic correlation.  Diagn Cytopathol. 1998;  19 423-427
  Google Scholar
• 135 Bipat S, Phoa S S, Delden O M. et al . Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis.  J Comput Assist Tomogr. 2005;  29 438-445
  Google Scholar
• 136 Dewitt van J, Devereaux B M, Lehman G A. et al . Comparison of endoscopic ultrasound and computed tomography for the preoperative evaluation of pancreatic cancer: a systematic review.  Clin Gastroenterol Hepatol. 2006;  4 717-725; quiz 664
  Google Scholar
• 137 Romagnuolo J, Bardou M, Rahme E. et al . Magnetic resonance cholangiopancreatography: a meta-analysis of test performance in suspected biliary disease.  Ann Intern Med. 2003;  139 547-557
  Google Scholar
• 138 Pakzad F, Groves A M, Ell P J. The role of positron emission tomography in the management of pancreatic cancer.  Semin Nucl Med. 2006;  36 248-256
  Google Scholar
• 139 Schachter P P, Avni Y, Shimonov M. et al . The impact of laparoscopy and laparoscopic ultrasonography on the management of pancreatic cancer.  Arch Surg. 2000;  135 1303-1307
  Google Scholar
• 140 Vollmer C M, Drebin J A, Middleton W D. et al . Utility of staging laparoscopy in subsets of peripancreatic and biliary malignancies.  Ann Surg. 2002;  235 1-7
  Google Scholar
• 141 van der Waaij L A, Dullemen H M, Porte R J. Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions. A pooled analysis.  Gastrointest Endosc. 2005;  62 383-389
  Google Scholar
• 142 Fong van Y, Blumgart L H, Fortner J G. et al . Pancreatic or liver resection for malignancy is safe and effective for the elderly.  Ann Surg. 1995;  222 426-434; discussion 434 - 437
  Google Scholar
• 143 Lightner A M, Glasgow R E, Jordan T H. et al . Pancreatic resection in the elderly.  J Am Coll Surg. 2004;  198 697-706
  Google Scholar
• 144 Lillemoe K D, Cameron J L, Hardacre J M. et al . Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial.  Ann Surg. 1999;  230 322-328; discussion 328 - 330
  Google Scholar
• 145 American College of Physicians . Guidelines for assessing and managing the perioperative risk from coronary artery disease associated with major noncardiac surgery.  Ann Intern Med. 1997;  127 309-312
  Google Scholar
• 146 Wagner M, Redaelli C, Lietz M. et al . Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma.  Br J Surg. 2004;  91 586-594
  Google Scholar
• 147 Fuhrman G M, Leach S D, Staley C A. et al . Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group.  Ann Surg. 1996;  223 154-162
  Google Scholar
• 148 Leach S D, Lee J E, Charnsangavej C. et al . Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head.  Br J Surg. 1998;  85 611-617
  Google Scholar
• 149 Sasson A R, Hoffman J P, Ross E A. et al . En bloc resection for locally advanced cancer of the pancreas: is it worthwhile?.  J Gastrointest Surg. 2002;  6 147-157; discussion 157 - 158
  Google Scholar
• 150 Nakao A, Takeda S, Inoue S. et al . Indications and techniques of extended resection for pancreatic cancer.  World J Surg. 2006;  30 976-982; discussion 983 - 984
  Google Scholar
• 151 Varadhachary G R, Tamm E P, Abbruzzese J L. et al . Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy.  Ann Surg Oncol. 2006;  13 1035-1046
  Google Scholar
• 152 Siriwardana H P, Siriwardena A K. Systematic review of outcome of synchronous portal-superior mesenteric vein resection during pancreatectomy for cancer.  Br J Surg. 2006;  93 662-673
  Google Scholar
• 153 Carrere N, Sauvanet A, Goere D. et al . Pancreaticoduodenectomy with mesentericoportal vein resection for adenocarcinoma of the pancreatic head.  World J Surg. 2006;  30 1526-1535
  Google Scholar
• 154 Riediger H, Makowiec F, Fischer E. et al . Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection.  J Gastrointest Surg. 2006;  10 1106-1115
  Google Scholar
• 155 Bachellier P, Nakano H, Oussoultzoglou P D. et al . Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile?.  Am J Surg. 2001;  182 120-129
  Google Scholar
• 156 Li B, Chen F Z, Ge X H. et al . Pancreatoduodenectomy with vascular reconstruction in treating carcinoma of the pancreatic head.  Hepatobiliary Pancreat Dis Int. 2004;  3 612-615
  Google Scholar
• 157 Settmacher U, Langrehr J M, Husmann I. et al . Reconstruction of visceral arteries with homografts in excision of the pancreas.  Chirurg. 2004;  75 1199-1206
  Google Scholar
• 158 Schwarz R E. Technical considerations to maintain a low frequency of postoperative biliary stent-associated infections.  J Hepatobiliary Pancreat Surg. 2002;  9 93-97
  Google Scholar
• 159 Gerke H, White R, Byrne M F. et al . Complications of pancreaticoduodenectomy after neoadjuvant chemoradiation in patients with and without preoperative biliary drainage.  Dig Liver Dis. 2004;  36 412-418
  Google Scholar
• 160 Jagannath P, Dhir V, Shrikhande S. et al . Effect of preoperative biliary stenting on immediate outcome after pancreaticoduodenectomy.  Br J Surg. 2005;  92 356-361
  Google Scholar
• 161 Martignoni M E, Wagner M, Krahenbuhl L. et al . Effect of preoperative biliary drainage on surgical outcome after pancreatoduodenectomy.  Am J Surg. 2001;  181 52-59; discussion 87
  Google Scholar
• 162 Sohn T A, Yeo C J, Cameron J L. et al . Do preoperative biliary stents increase postpancreaticoduodenectomy complications?.  J Gastrointest Surg. 2000;  4 258-267; discussion 267 - 268
  Google Scholar
• 163 Targarona E M, Garau J, Munoz-Ramos C. et al . Single-dose antibiotic prophylaxis in patients at high risk for infection in biliary surgery: a prospective and randomized study comparing cefonicid with mezlocillin.  Surgery. 1990;  107 327-334
  Google Scholar
• 164 Kujath P, Bouchard R, Scheele J. et al . Current perioperative antibiotic prophylaxis.  Chirurg. 2006;  77 490, 492-498
  Google Scholar
• 165 Connor S, Alexakis N, Garden O J. et al . Meta-analysis of the value of somatostatin and its analogues in reducing complications associated with pancreatic surgery.  Br J Surg. 2005;  92 1059-1067
  Google Scholar
• 166 Bassi C, Dervenis C, Butturini G. et al . Postoperative pancreatic fistula: an international study group (ISGPF) definition.  Surgery. 2005;  138 8-13
  Google Scholar
• 167 Finlayson C, Hoffman J, Yeung R. et al . Intraoperative ultrasound does not improve detection of liver metastases in resectable pancreatic cancer.  Am J Surg. 1998;  175 99-101
  Google Scholar
• 168 Kolecki R, Schirmer B. Intraoperative and laparoscopic ultrasound.  Surg Clin North Am. 1998;  78 251-271
  Google Scholar
• 169 Warshaw A L, Fernandez-del Castillo C. Pancreatic carcinoma.  N Engl J Med. 1992;  326 455-465
  Google Scholar
• 170 Konishi M, Kinoshita T, Nakagohri T. et al . Prognostic value of cytologic examination of peritoneal washings in pancreatic cancer.  Arch Surg. 2002;  137 475-480
  Google Scholar
• 171 Yachida S, Fukushima N, Sakamoto M. et al . Implications of peritoneal washing cytology in patients with potentially resectable pancreatic cancer.  Br J Surg. 2002;  89 573-578
  Google Scholar
• 172 Diener M K, Knaebel H P, Heukaufer C. et al . A Systematic Review and Meta-analysis of Pylorus-preserving Versus Classical Pancreaticoduodenectomy for Surgical Treatment of Periampullary and Pancreatic Carcinoma.  Ann Surg. 2007;  245 187-200
  Google Scholar
• 173 Christein J D, Kendrick M L, Iqbal C W. et al . Distal pancreatectomy for resectable adenocarcinoma of the body and tail of the pancreas.  J Gastrointest Surg. 2005;  9 922-927
  Google Scholar
• 174 Shimada K, Sakamoto Y, Sano T. et al . Prognostic factors after distal pancreatectomy with extended lymphadenectomy for invasive pancreatic adenocarcinoma of the body and tail.  Surgery. 2006;  139 288-295
  Google Scholar
• 175 Shoup M, Conlon K C, Klimstra D. et al . Is extended resection for adenocarcinoma of the body or tail of the pancreas justified?.  J Gastrointest Surg. 2003;  7 946-952; discussion 952
  Google Scholar
• 176 Pedrazzoli S, DiCarlo V, Dionigi R. et al . Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group.  Ann Surg. 1998;  228 508-517
  Google Scholar
• 177 Farnell M B, Pearson R K, Sarr M G. et al . A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma.  Surgery. 2005;  138 618-628; discussion 628 - 630
  Google Scholar
• 178 Yeo C J, Cameron J L, Lillemoe K D. et al . Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality.  Ann Surg. 2002;  236 355-366; discussion 366 - 368
  Google Scholar
• 179 Brugge W R, Lauwers G Y, Sahani D. et al . Cystic neoplasms of the pancreas.  N Engl J Med. 2004;  351 1218-1226
  Google Scholar
• 180 Brugge W R, Lewandrowski K, Lee-Lewandrowski E. et al . Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study.  Gastroenterology. 2004;  126 1330-1336
  Google Scholar
• 181 Sedlack R, Affi A, Vazquez-Sequeiros E. et al . Utility of EUS in the evaluation of cystic pancreatic lesions.  Gastrointest Endosc. 2002;  56 543-547
  Google Scholar
• 182 Salvia R, Fernandez-del C astillo C, Bassi C. et al . Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection.  Ann Surg. 2004;  239 678-685; discussion 685 - 687
  Google Scholar
• 183 Bassi C, Salvia R, Molinari E. et al . Management of 100 consecutive cases of pancreatic serous cystadenoma: wait for symptoms and see at imaging or vice versa?.  World J Surg. 2003;  27 319-323
  Google Scholar
• 184 Hirano S, Kondo S, Ambo Y. et al . Outcome of duodenum-preserving resection of the head of the pancreas for intraductal papillary-mucinous neoplasm.  Dig Surg. 2004;  21 242-245
  Google Scholar
• 185 Takada T, Yasuda H, Amano H. et al . Simultaneous hepatic resection with pancreato-duodenectomy for metastatic pancreatic head carcinoma: does it improve survival?.  Hepatogastroenterology. 1997;  44 567-573
  Google Scholar
• 186 Mann O, Strate T, Schneider C. et al . Surgery for advanced and metastatic pancreatic cancer - current state and perspectives.  Anticancer Res. 2006;  26 681-686
  Google Scholar
• 187 Shrikhande S V, Kleeff J, Reiser C. et al . Pancreatic resection for M1 pancreatic ductal adenocarcinoma.  Ann Surg Oncol. 2007;  14 118-127
  Google Scholar
• 188 Friess H, Kleeff J, Silva J C. et al . The role of diagnostic laparoscopy in pancreatic and periampullary malignancies.  J Am Coll Surg. 1998;  186 675-682
  Google Scholar
• 189 Urbach D R, Swanstrom L L, Hansen P D. The effect of laparoscopy on survival in pancreatic cancer.  Arch Surg. 2002;  137 191-199
  Google Scholar
• 190 Santoro E, Carlini M, Carboni F. Laparoscopic pancreatic surgery: indications, techniques and preliminary results.  Hepatogastroenterology. 1999;  46 1174-1180
  Google Scholar
• 191 Cioc A M, Ellison E C, Proca D M. et al . Frozen section diagnosis of pancreatic lesions.  Arch Pathol Lab Med. 2002;  126 1169-1173
  Google Scholar
• 192 Luttges J, Zamboni G, Kloppel G. Recommendation for the examination of pancreaticoduodenectomy specimens removed from patients with carcinoma of the exocrine pancreas. A proposal for a standardized pathological staging of pancreaticoduodenectomy specimens including a checklist.  Dig Surg. 1999;  16 291-296
  Google Scholar
• 193 Compton C C, Henson D E. Protocol for the examination of specimens removed from patients with carcinoma of the exocrine pancreas: a basis for checklists. Cancer Committee, College of American Pathologists.  Arch Pathol Lab Med. 1997;  121 1129-1136
  Google Scholar
• 194 Sakata E, Shirai Y, Yokoyama N. et al . Clinical significance of lymph node micrometastasis in ampullary carcinoma.  World J Surg. 2006;  30 985-991
  Google Scholar
• 195 Oettle H, Post S, Neuhaus P. et al . Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.  Jama. 2007;  297 267-277
  Google Scholar
• 196 Stocken D D, Buchler M W, Dervenis C. et al . Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer.  Br J Cancer. 2005;  92 1372-1381
  Google Scholar
• 197 Neoptolemos J P, Stocken D D, Friess H. et al . A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.  N Engl J Med. 2004;  350 1200-1210
  Google Scholar
• 198 Penberthy D R, Rich T A, Shelton C H. et al . A pilot study of chronomodulated infusional 5-fluorouracil chemoradiation for pancreatic cancer.  Ann Oncol. 2001;  12 681-684
  Google Scholar
• 199 Mallinson C N, Rake M O, Cocking J B. et al . Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial.  Br Med J. 1980;  281 1589-1591
  Google Scholar
• 200 Palmer K R, Kerr M, Knowles G. et al . Chemotherapy prolongs survival in inoperable pancreatic carcinoma.  Br J Surg. 1994;  81 882-885
  Google Scholar
• 201 Glimelius B, Hoffman K, Sjoden P O. et al . Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer.  Ann Oncol. 1996;  7 593-600
  Google Scholar
• 202 Yip D, Karapetis C, Strickland A. et al . Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer.  Cochrane Database Syst Rev 3 CD002093. 2006; 
  Google Scholar
• 203 Burris H A 3rd , Moore M J, Andersen J. et al . Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.  J Clin Oncol. 1997;  15 2403-2413
  Google Scholar
• 204 Storniolo A M, Enas N H, Brown C A. et al . An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma.  Cancer. 1999;  85 1261-1268
  Google Scholar
• 205 Louvet C, Labianca R, Hammel P. et al . Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.  J Clin Oncol. 2005;  23 3509-3516
  Google Scholar
• 206 Heinemann V, Quietzsch D, Gieseler F. et al . Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.  J Clin Oncol. 2006;  24 3946-3952
  Google Scholar
• 207 Herrmann R, Bodoky G, Rushstaller T. et al . Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer: a randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG).  J Clin Oncol. 2005;  23 A4010
  Google Scholar
• 208 Berlin J D, Catalano P, Thomas J P. et al . Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.  J Clin Oncol. 2002;  20 3270-3275
  Google Scholar
• 209 Van Cutsem E, Velde van de H, Karasek P. et al . Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.  J Clin Oncol. 2004;  22 1430-1438
  Google Scholar
• 210 Tempero M, Plunkett W, Ruiz Van Haperen V. et al . Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.  J Clin Oncol. 2003;  21 3402-3408
  Google Scholar
• 211 Poplin E, Levy D, Berlin J. et al . Phase III trial of gemcitabine (30 min infusion) versus gemcitabine (fixed-dose rate infusion (FDR) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201).  J Clin Oncol. 2006;  24 LBA4004
  Google Scholar
• 212 Maisey N, Chau I, Cunningham D. et al . Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer.  J Clin Oncol. 2002;  20 3130-3136
  Google Scholar
• 213 Ducreux M, Rougier P, Pignon J P. et al . A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma.  Ann Oncol. 2002;  13 1185-1191
  Google Scholar
• 214 Lutz M P, Koniger M, Muche R. et al . A phase II study of weekly 24-h infusion of high-dose 5-fluorouracil in advanced pancreatic cancer.  Z Gastroenterol. 1999;  37 993-997
  Google Scholar
• 215 Colucci G, Giuliani F, Gebbia V. et al . Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell’Italia Meridionale.  Cancer. 2002;  94 902-910
  Google Scholar
• 216 Ducreux M, Mitry E, Ould-Kaci M. et al . Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients.  Ann Oncol. 2004;  15 467-473
  Google Scholar
• 217 Cunningham D, Chau I, Stocken D D. et al . Phase III randomized comparison of gemcitabine (GEM) vs. gemcitabine plus capecitabine (Gem-CAP) in patients with advanced pancreatic cancer.  Eur J Cancer. 2005;  3 PS11
  Google Scholar
• 218 Di Costanzo F, Carlini P, Doni L. et al . Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC).  Br J Cancer. 2005;  93 185-189
  Google Scholar
• 219 Riess M, Helm A, Niedergethmann I. et al . A randomised prospective, multicentre phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer.  J Clin Oncol. 2005;  23 A1092
  Google Scholar
• 220 Moore M J, Goldstein D, Hamm J. et al . Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.  J Clin Oncol. 2007;  15 1960-6
  Google Scholar
• 221 Kindler H L, Friberg G, Singh D A. et al . Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer.  J Clin Oncol. 2005;  23 8033-8040
  Google Scholar
• 222 Kindler H, Niedzwiecki, Hollis D. et al . A double-blind, placebo controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB) 80 303.  Proceedings of the ASCO Gastrointestinal Cancers Symposium. 2007;  A108
  Google Scholar
• 223 Reni M, Passoni P, Bonetto E. et al . Final results of a prospective trial of a PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma.  Oncology. 2005;  68 239-245
  Google Scholar
• 224 Lutz M P, Van Cutsem E, Wagener T. et al . Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40 984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group.  J Clin Oncol. 2005;  23 9250-9256
  Google Scholar
• 225 Shepard R C, Levy D E, Berlin J D. et al . Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group.  Oncology. 2004;  66 303-309
  Google Scholar
• 226 Ridwelski K, Fahlke J, Kuhn R. et al . Multicenter phase-I/II study using a combination of gemcitabine and docetaxel in metastasized and unresectable, locally advanced pancreatic carcinoma.  Eur J Surg Oncol. 2006;  32 297-302
  Google Scholar
• 227 Jacobs A D, Otero H, Picozzi V J Jr. et al . Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma.  Cancer Invest. 2004;  22 505-514
  Google Scholar
• 228 Ulrich-Pur H, Raderer M, Verena Kornek G. et al . Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.  Br J Cancer. 2003;  88 1180-1184
  Google Scholar
• 229 Tsavaris N, Kosmas C, Skopelitis H. et al . Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.  Invest New Drugs. 2005;  23 369-375
  Google Scholar
• 230 Reni M, Pasetto L, Aprile G. et al . Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.  Br J Cancer. 2006;  94 785-791
  Google Scholar
• 231 Demols A, Peeters M, Polus M. et al . Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study.  Br J Cancer. 2006;  94 481-485
  Google Scholar
• 232 Oettle H, Arnold D, Esser M. et al . Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma.  Anticancer Drugs. 2000;  11 635-638
  Google Scholar
• 233 Burris H A 3rd , Rivkin S, Reynolds R. et al . Phase II trial of oral rubitecan in previously treated pancreatic cancer patients.  Oncologist. 2005;  10 183-190
  Google Scholar
• 234 Mitry E, Ducreux M, Ould-Kaci M. et al . Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial.  Gastroenterol Clin Biol. 2006;  30 357-363
  Google Scholar
• 235 Willett C G, Czito B G, Bendell J C. et al . Locally advanced pancreatic cancer.  J Clin Oncol. 2005;  23 4538-4544
  Google Scholar
• 236 Moertel C G, Childs D S Jr, Reitemeier R J. et al . Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer.  Lancet. 1969;  2 865-867
  Google Scholar
• 237 Moertel C G, Frytak S, Hahn R G. et al . Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.  Cancer. 1981;  48 1705-1710
  Google Scholar
• 238 Klaassen D J, MacIntyre J M, Catton G E. et al . Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil - an Eastern Cooperative Oncology Group study.  J Clin Oncol. 1985;  3 373-378
  Google Scholar
• 239 Cohen L, Woodruff K H, Hendrickson F R. et al . Response of pancreatic cancer to local irradiation with high-energy neutrons.  Cancer. 1985;  56 1235-1241
  Google Scholar
• 240 Cohen S J, Dobelbower R Jr, Lipsitz S. et al . A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282.  Int J Radiat Oncol Biol Phys. 2005;  62 1345-1350
  Google Scholar
• 241 Gastrointestinal Tumor Study Group . Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone.  J Natl Cancer Inst. 1988;  80 751-755
  Google Scholar
• 242 Shinchi H, Takao S, Noma H. et al . Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer.  Int J Radiat Oncol Biol Phys. 2002;  53 146-150
  Google Scholar
• 243 McGinn C J, Zalupski M M, Shureiqi I. et al . Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.  J Clin Oncol. 2001;  19 4202-4208
  Google Scholar
• 244 Kachnic L A, Shaw J E, Manning M A. et al . Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas.  Int J Cancer. 2001;  96 132-139
  Google Scholar
• 245 Crane C H, Abbruzzese J L, Evans D B. et al . Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?.  Int J Radiat Oncol Biol Phys. 2002;  52 1293-1302
  Google Scholar
• 246 Rocha Lima C M, Green M R, Rotche R. et al . Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.  J Clin Oncol. 2004;  22 3776-3783
  Google Scholar
• 247 Chauffert B, Mornex F, Bonnetain F. et al . Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study.  J Clin Oncol. 2006;  24 A4008
  Google Scholar
• 248 Huguet F, Andre T, Hammel P. et al . Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR Phase II and III studies.  J Clin Oncol. 2007;  20 326-331
  Google Scholar
• 249 Sa Cunha A, Rault A, Laurent C. et al . Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas.  J Am Coll Surg. 2005;  201 359-365
  Google Scholar
• 250 Fisher B J, Perera F E, Kocha W. et al . Analysis of the clinical benefit of 5-fluorouracil and radiation treatment in locally advanced pancreatic cancer.  Int J Radiat Oncol Biol Phys. 1999;  45 291-295
  Google Scholar
• 251 Furuse J, Kinoshita T, Kawashima M. et al . Intraoperative and conformal external-beam radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic carcinoma.  Cancer. 2003;  97 1346-1352
  Google Scholar
• 252 Brunner T B, Grabenbauer G G, Kastl S. et al . Preoperative Chemoradiation in Locally Advanced Pancreatic Carcinoma: A Phase II Study.  Onkologie. 2000;  23 436-442
  Google Scholar
• 253 Ikeda M, Okada S, Tokuuye K. et al . A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer.  Br J Cancer. 2002;  86 1551-1554
  Google Scholar
• 254 Talamonti M S, Catalano P J, Vaughn D J. et al . Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity.  J Clin Oncol. 2000;  18 3384-3389
  Google Scholar
• 255 Brunner T B, Grabenbauer G G, Klein P. et al . Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer.  Int J Radiat Oncol Biol Phys. 2003;  55 144-153
  Google Scholar
• 256 Micke O, Hesselmann S, Bruns F. et al . Results and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy.  Anticancer Res. 2005;  25 1523-1530
  Google Scholar
• 257 Xiong H Q, Rosenberg A, LoBuglio A. et al . Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.  J Clin Oncol. 2004;  22 2610-2616
  Google Scholar
• 258 Bramhall S R, Rosemurgy A, Brown P D. et al . Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial.  J Clin Oncol. 2001;  19 3447-3455
  Google Scholar
• 259 Moore M J, Hamm J, Dancey J. et al . Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12 - 9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.  J Clin Oncol. 2003;  21 3296-3302
  Google Scholar
• 260 Beger H G, Link K H, Gansauge F. Adjuvant regional chemotherapy in advanced pancreatic cancer: results of a prospective study.  Hepatogastroenterology. 1998;  45 638-643
  Google Scholar
• 261 Ghaneh P, Neoptolemos J P. Conclusions from the European Study Group for Pancreatic Cancer adjuvant trial of chemoradiotherapy and chemotherapy for pancreatic cancer.  Surg Oncol Clin N Am. 2004;  13 567-587, vii-viii
  Google Scholar
• 262 Lohr M, Hoffmeyer A, Kroger J. et al . Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma.  Lancet. 2001;  357 1591-1592
  Google Scholar
• 263 Mercadante S. Pain treatment and outcomes for patients with advanced cancer who receive follow-up care at home.  Cancer. 1999;  85 1849-1858
  Google Scholar
• 264 Zech D F, Grond S, Lynch J. et al . Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study.  Pain. 1995;  63 65-76
  Google Scholar
• 265 Marinangeli F, Ciccozzi A, Leonardis M. et al . Use of strong opioids in advanced cancer pain: a randomized trial.  J Pain Symptom Manage. 2004;  27 409-416
  Google Scholar
• 266 Grahm A L, Andren-Sandberg A. Prospective evaluation of pain in exocrine pancreatic cancer.  Digestion. 1997;  58 542-549
  Google Scholar
• 267 Caraceni A, Portenoy R K. Pain management in patients with pancreatic carcinoma.  Cancer. 1996;  78 639-653
  Google Scholar
• 268 Ross G J, Kessler H B, Clair M R. et al . Sonographically guided paracentesis for palliation of symptomatic malignant ascites.  Am J Roentgenol. 1989;  153 1309-1311
  Google Scholar
• 269 McNicol E, Strassels S, Goudas L. et al . Nonsteroidal anti-inflammatory drugs, alone or combined with opioids, for cancer pain: a systematic review.  J Clin Oncol. 2004;  22 1975-1992
  Google Scholar
• 270 Carr D B, Goudas L C, Balk E M. et al . Evidence report on the treatment of pain in cancer patients.  J Natl Cancer Inst Monogr. 2004;  32 23-31
  Google Scholar
• 271 Payne R, Mathias S D, Pasta D J. et al . Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine.  J Clin Oncol. 1998;  16 1588-1593
  Google Scholar
• 272 De Conno F, Ripamonti C, Saita L. et al . Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain.  J Clin Oncol. 1995;  13 1004-1008
  Google Scholar
• 273 Cherny N I. The management of cancer pain.  CA Cancer J Clin. 2000;  50 70-116; quiz 117 - 120
  Google Scholar
• 274 Gilmer-Hill H S, Boggan J E, Smith K A. et al . Intrathecal morphine delivered via subcutaneous pump for intractable pain in pancreatic cancer.  Surg Neurol. 1999;  51 6-11
  Google Scholar
• 275 Staats P S, Hekmat H, Sauter P. et al . The effects of alcohol celiac plexus block, pain, and mood on longevity in patients with unresectable pancreatic cancer: a double-blind, randomized, placebo-controlled study.  Pain Med. 2001;  2 28-34
  Google Scholar
• 276 Eisenberg E, Carr D B, Chalmers T C. Neurolytic celiac plexus block for treatment of cancer pain: a meta-analysis.  Anesth Analg. 1995;  80 290-295
  Google Scholar
• 277 Wong G Y, Schroeder D R, Carns P E. et al . Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial.  Jama. 2004;  291 1092-1099
  Google Scholar
• 278 Stefaniak T, Basinski A, Vingerhoets A. et al . A comparison of two invasive techniques in the management of intractable pain due to inoperable pancreatic cancer: neurolytic celiac plexus block and videothoracoscopic splanchnicectomy.  Eur J Surg Oncol. 2005;  31 768-773
  Google Scholar
• 279 Arends J, Bodoky G, Bozzetti F. et al . ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology.  Clin Nutr. 2006;  25 245-259
  Google Scholar
• 280 Arends J, Zuercher G, Fietkau R. et al . DGEM Leitlinie Enterale Ernährung: Onkologie.  Akt Ernähr Med. 2003;  28 61-68
  Google Scholar
• 281 Bjelakovic G, Nikolova D, Gluud L L. et al . Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis.  Jama. 2007;  297 842-857
  Google Scholar
• 282 Wigmore S J, Falconer J S, Plester C E. et al . Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients.  Br J Cancer. 1995;  72 185-188
  Google Scholar
• 283 Gordon J N, Trebble T M, Ellis R D. et al . Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial.  Gut. 2005;  54 540-545
  Google Scholar
• 284 Jatoi A, Windschitl H E, Loprinzi C L. et al . Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study.  J Clin Oncol. 2002;  20 567-573
  Google Scholar
• 285 Loprinzi C L, Kugler J W, Sloan J A. et al . Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia.  J Clin Oncol. 1999;  17 3299-3306
  Google Scholar
• 286 Moss A C, Morris E, Mac Mathuna P. Palliative biliary stents for obstructing pancreatic carcinoma.  Cochrane Database Syst Rev CD004200. 2006; 
  Google Scholar
• 287 Hausegger K A, Thurnher S, Bodendorfer G. et al . Treatment of malignant biliary obstruction with polyurethane-covered Wallstents.  AJR Am J Roentgenol. 1998;  170 403-408
  Google Scholar
• 288 Isayama H, Komatsu Y, Tsujino T. et al . A prospective randomised study of „covered” versus „uncovered” diamond stents for the management of distal malignant biliary obstruction.  Gut. 2004;  53 729-734
  Google Scholar
• 289 Speer A G, Cotton P B, Russell R C. et al . Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice.  Lancet. 1987;  2 57-62
  Google Scholar
• 290 Urbach D R, Bell C M, Swanstrom L L. et al . Cohort study of surgical bypass to the gallbladder or bile duct for the palliation of jaundice due to pancreatic cancer.  Ann Surg. 2003;  237 86-93
  Google Scholar
• 291 DiFronzo L A, Egrari S, O’Connell T X. Choledochoduodenostomy for palliation in unresectable pancreatic cancer.  Arch Surg. 1998;  133 820-825
  Google Scholar
• 292 Aranha G V, Prinz R A, Greenlee H B. Biliary enteric bypass for benign and malignant disease.  Am Surg. 1987;  53 403-406
  Google Scholar
• 293 Song H Y, Shin J H, Yoon C J. et al . A dual expandable nitinol stent: experience in 102 patients with malignant gastroduodenal strictures.  J Vasc Interv Radiol. 2004;  15 1443-1449
  Google Scholar
• 294 Kaw M, Singh S, Gagneja H. et al . Role of self-expandable metal stents in the palliation of malignant duodenal obstruction.  Surg Endosc. 2003;  17 646-650
  Google Scholar
• 295 Smith T J, Khatcheressian J, Lyman G H. et al . 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.  J Clin Oncol. 2006;  24 3187-3205
  Google Scholar
• 296 Rizzo J D, Lichtin A E, Woolf S H. et al . Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.  J Clin Oncol. 2002;  20 4083-4107
  Google Scholar
• 297 Bokemeyer C, Aapro M S, Courdi A. et al . EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.  Eur J Cancer. 2007;  43 258-270
  Google Scholar
• 298 Schuchter L M, Hensley M L, Meropol N J. et al . 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology.  J Clin Oncol. 2002;  20 2895-2903
  Google Scholar

Prof. Guido Adler

Klinik für Innere Medizin I,
Universitätsklinikum Ulm

Robert-Koch-Straße 8

89081 Ulm

Phone: ++ 49/7 31/50 04 45 00

Fax: ++ 49/7 31/50 04 45 02

Email: guido.adler@uniklinik-ulm.de